论文部分内容阅读
Objective To investigate the optimal dose of GnRH-a, which is sufficient for down regulation of pituitary without over-suppression of ovarian function in IVF superovulation protocols Methods Sixty patients undertook IVF-ET because of tube factor and /or endometriosis. Patients were divided into three groups randomly. Group A: 25 patients received a single dose of 1.88 mg Decapeptyl; Group B: 20 patients had a single dose of 2.50 mg Decapeptyl; Group C: 15 patients had a single dose of 3.75 mg Decapeptyl. Results The LH levels were 2.00±0.77 IU/L in Group A, 1.05±0.44 IU/L and 0.95 ±0.48 IU/L in Group B and C respectively on the day of starting gonadotropin injection; 1.97±0.76 IU/L in Group A, 0.96±0.42 IU/L and 0.77±0.49 IU/L in Group B and C respectively on the day of hCG administration. The LH levels in Group B and Group C were significantly lower than those in Group A (P<0.01). The mean number of gonadotropin ampoules was higher in Group B (38.05±6.08 ampoules) and Group C (40.0±10.62 ampoules) than in Group A (29.96±4.98 ampoules) (P< 0.01). The duration of stimulation significantly increased in Group B (12.9±1.81 d) and Group C (13.6±2.63 d) as compared with that in Group A (11.24±1.36 d) (P<0.01). There were no differences among three groups in E_2 levels on the day of hCG administration, the number of retrieved oocytes, fertilization rate, cleavage rate or pregnancy rate. There was no presence of LH peak in all groups. Conclusion The use of 1.88 mg Decapeptyl provides successful rate similar to 2.50 mg and 3.75 mg Decapeptyl, resulting in the reduced amount of gonadotropin, the duration of stimulation and the cost of treatment. The dose of 1.88 mg Decapeptyl is sufficient for pituitary down-regulation of IVF program for Chinese women.
Objective To investigate the optimal dose of GnRH-a, which is sufficient for down regulation of pituitary without over-suppression of ovarian function in IVF superovulation protocols Methods Sixty patients under investigation IVF-ET because of tube factor and / or endometriosis. Patients were divided into Group A: 25 patients received a single dose of 1.88 mg Decapeptyl; Group B: 20 patients had a single dose of 2.50 mg Decapeptyl; Group C: 15 patients had a single dose of 3.75 mg Decapeptyl. Results The LH levels were 2.00 ± 0.77 IU / L in Group A, 1.05 ± 0.44 IU / L and 0.95 ± 0.48 IU / L in Group B and C respectively on the day of starting gonadotropin injection; 1.97 ± 0.76 IU / L in Group A, 0.96 ± 0.42 IU / L and 0.77 ± 0.49 IU / L in Group B and C respectively on the day of hCG administration. The LH levels in Group B and Group C were significantly lower than those in Group A (P <0.01). The mean number of gonadotropin ampoules was higher in Group B (38.05 ± 6.08 ampoules) and Group C (40.0 ± 10.62 ampoules) than in Group A (29.96 ± 4.98 ampoules) (P <0.01). The duration of stimulation significantly increased in Group B (12.9 ± 1.81 d) and Group C with that in Group A (11.24 ± 1.36 d) (P <0.01). There were no differences among three groups in E_2 levels on the day of hCG administration, the number of retrieved oocytes, fertilization rate, cleavage rate or pregnancy rate. There was no presence of LH peak in all groups. Conclusion The use of 1.88 mg Decapeptyl provides similar rates of 2.50 mg and 3.75 mg Decapeptyl, resulting in the reduced amount of gonadotropin, the duration of stimulation and the cost of treatment. 1.88 mg Decapeptyl is sufficient for pituitary down-regulation of IVF program for Chinese women.